Note: Live price is not available for this stock. Showing closing price. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
SUVEN Stock Analysis
Views
Red Flags
Positive
Low Debt to Equity, not much change from last year
Company is net cash
Negative
Stock is fairly expensive with negative EPS on a trailing 12-month basis
Low and declining ROE
Low and declining operating margin
Low revenue growth and lower than median growth of industry
Low EPS growth and lower than median growth of industry
Low dividend yield
Neutral
Company's earnings are of moderate quality
No red flags found!
No significant red flags found in the stock.
Snapshot
See detailed analysis
SUVEN Shareholding Pattern
An overview of who owns the company. Click on chart icon to view historical movement.
SUVEN Bulk, Block & Insider Trades
SUVEN Dividends, Splits & Bonus
Dividend Events
Capital Change Events
Rights issue
Stock split
Others
Rights issue(1 new shares @ 55 INR for 2 existing shares) Ex-date: 17th Oct 2022 Announced on: 12th Oct 2022
Stock split(1 : 5)Nominal value change from Rs. 10 to Rs. 2. Ex-date: 16th Jan 2004 Announced on: 29th Dec 2003
Demerger (DEM)Demerger of suven life sciences limited to Suven pharmaceuticals ltd as Resulting company.The demerged company shall pay each share holding 1 fully paid up equity of INR 1 of the resulting company for every 1 fully paid equity share of INR 1. Ex-date: 21st Jan 2020 Announced on: 5th Feb 2019
Complex capital change1. Nominal value changed from Rs 2 to Rs 1 each. 2. Bonus issue of 57633250 securities. Ex-date: 23rd Mar 2007 Announced on: 29th Jan 2007
Company Profile
Suven Life Sciences Limited is an India-based biopharmaceutical company, which is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The Companys lead clinical-stage assets include Masupirdine (... Read More
Key personnel
Shri. Venkateswarlu (Venkat) JastiD
Executive Chairman of the Board, Managing Director
Mr. M. Mohan Kumar
Chief Financial Officer
Mr. Shrenik Soni
Chief Compliance Officer, Company Secretary
Smt. Sudha Rani JastiD
Wholetime Director
Prof. Dr. Syed E. Hasnain, Ph.D.D
Non-Executive Director
Shri. Santanu MukherjeeD
Independent Non-Executive Director
Smt. J.A.S PadmajaD
Non-Executive Independent Director
Mr. Vajja Sambasiva RaoD
Additional Non-Executive Independent Director
Incorporated on
Last Annual
Last Interim
No. of Employees
IPO date
Free Float
Address
Frequently asked questions
What is the current share price of Suven Life Sciences Ltd.?
The current share price of Suven Life Sciences Ltd. is ₹ 154.27 as of 14 Jan 2026.
What is the PE ratio of Suven Life Sciences Ltd.?
The Price-to-Earnings (PE) ratio of Suven Life Sciences Ltd. is - as of the latest financial data.
What is the ROE and ROCE of Suven Life Sciences Ltd.?
Suven Life Sciences Ltd. has a Return on Equity (ROE) of -77.74% and a Return on Capital Employed (ROCE) of -92.41% as per the latest financial reports.
What is the market cap of Suven Life Sciences Ltd.?
The market capitalization of Suven Life Sciences Ltd. stands at ₹ 3,509.24 Cr.
What is the dividend yield of Suven Life Sciences Ltd.?
The dividend yield of Suven Life Sciences Ltd. is 0.00% based on the current market price.
What is the RSI of Suven Life Sciences Ltd.?
The Relative Strength Index (RSI) of Suven Life Sciences Ltd. is 35.64.
What is the FII and DII holding in Suven Life Sciences Ltd.?
Foreign Institutional Investors (FII) hold 1.07% and Domestic Institutional Investors (DII) hold 2.08% of Suven Life Sciences Ltd. shares.
What sector does Suven Life Sciences Ltd. belong to?
Suven Life Sciences Ltd. operates in the Healthcare sector.
What is the beta of Suven Life Sciences Ltd. stock?
The beta of Suven Life Sciences Ltd. stock is 0.92, indicating its volatility relative to the broader market.
